Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Clinical trial NCT07312578 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07312578
- Sponsor
- Peking University
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-01
- Primary completion
- 2027-11-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.